Moreover, high levels of MET amplification defined as MET:CEP7 > 5 were previously identified as actionable driver mutations predicting sensitivity of the tumor to the inhibitors of kinase MET, including crizotinib, currently approved for the treatment of ALK or ROS1-rearranged lung cancers [62]. Here, ALK is linked to lung cancer.